Our observation of attenuated liver steatosis with impaired VIP signaling to ILC3 prompted us to evaluate whether the global modulation of VIP-neurons would be feasible in the setting of MASLD. This evidence concerns the gene VIP and metabolic dysfunction-associated steatotic liver disease.